Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Omega-3 Firms Angle For Sustainability With Supply Under Pressure

This article was originally published in The Tan Sheet

Executive Summary

Fish oil prices are soaring as the global stock shrinks in relation to climbing demand. Sustainable fishery certification has become widespread, but major omega-3 players still hedge their bets by diversifying into multiple ingredient sources, including krill.

You may also be interested in...



Reckitt Deals Feed OTC Domination Plan

Reckitt Benckiser CEO Rakesh Kapoor plays up the firm’s potential to dominate the fragmented global consumer health product market and says Reckitt is better positioned than big pharma firms to manage OTC businesses. Reckitt continued its emerging markets focus with OTC deals in Latin America and China.

GOED China Office Launch Underscores Omega-3s’ Global Scope

The Global Organization for EPA and DHA Omega-3s in 2013 will open its doors in China, its first satellite office. The trade group also hopes to submit health claim applications to FDA this year regarding the benefits of omega-3 fatty acids on blood pressure and heart health.

DSM Makes Waves In Omega-3 Fish Oil With Ocean Nutrition Pick-Up

The Dutch ingredients company hopes to expand Ocean Nutrition Canada into a global omega-3 fish oil supplier for foods and supplements, as well as a source for pharma ingredients. With expiring IP on the Martek algal DHA process, DSM could be seeking a hedge.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel